Cancer Immunotherapy Market Growth, Trends & Opportunities | Latest Global Analysis 2025 | Leading key players - AstraZeneca, Pfizer Inc., F. Hoffmann-La Roche Ltd.

Cancer Immunotherapy Market, as analyzed in the study by DataM Intelligence, presents a detailed overview of the industry with in-depth insights, historical data, and key statistics. The report thoroughly examines market dynamics, competitive strategies, and major players, highlighting their product lines, pricing structures, financials, growth plans, and regional outreach.

The Cancer Immunotherapy Market reached US$ 137.70 billion in 2024 and is expected to reach US$ 261.74 billion by 2033, growing at a CAGR of 7.9% during the forecast period 2025-2033.

Get a Premium Sample PDF Of This Report (Get Higher Priority for Corporate Email ID) @ https://datamintelligence.com/download-sample/cancer-immunotherapy-market?sz

The Cancer Immunotherapy Market involves treatments that empower the body's immune system to identify and fight cancer cells. These therapies include immune checkpoint inhibitors, CAR-T cell therapy, vaccines, and monoclonal antibodies. By enhancing natural defenses, cancer immunotherapy offers targeted, effective options with fewer side effects compared to traditional treatments like chemotherapy or radiation.

Major players in the Cancer Immunotherapy Market

The prominent players in Cancer Immunotherapy market research report are: Merck & Co., Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, AstraZeneca, Pfizer Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Kite Pharma, Inc., Dendreon Pharmaceuticals LLC., and Amgen Inc., among others.

The companies are primarily focusing on strategies such as new product launches to penetrate the fastest-growing emerging markets across the world.

Key Development

In April 2025, Akeso, Inc. announced that China's National Medical Products Administration (NMPA) approved the supplemental new drug application for ivonescimab. This immunotherapy is a first-in-class PD-1/VEGF bispecific antibody, authorized as monotherapy for first-line treatment of PD-L1-positive non-small cell lung cancer (NSCLC) patients who test negative for EGFR and ALK gene mutations.

In September 2024, MSD (known as Merck in the U.S. and Canada) received approval in Japan for Keytruda (pembrolizumab) to treat certain patients with non-small cell lung carcinoma (NSCLC) and radically unresectable urothelial carcinoma.

Speak to Our Senior Analyst and Get Customization in the report as per your requirements @ https://datamintelligence.com/customize/cancer-immunotherapy-market

Market Segments

By Type: Immune Checkpoint Inhibitors, Cytokines, Cancer Vaccines, Adoptive Cell Therapy, Other Immunotherapies.

By Indication: Non-Small Cell Lung Cancer (NSCLC), Melanoma, Colorectal Cancer, Renal Cell Carcinoma, Breast Cancer, Bladder Cancer, Others.

The Cancer Immunotherapy industry is experiencing rapid growth, driven by advancements in medical technologies, increased demand for innovative therapies, and a rising focus on patient-centered care. As these sectors evolve, the need for comprehensive market analysis becomes crucial to understand trends, regulatory changes, and emerging opportunities.

Regions Covered:

The global Cancer Immunotherapy Market report focuses on six major regions: North America, South America, Europe, Asia Pacific, the Middle East, and Africa.

☞ North America - US, Canada, Mexico

☞ Europe- Germany, Russia, UK, France, Italy, Rest of Europe

☞ Asia Pacific- China, India, Japan, Australia, Rest of Asia Pacific

☞ South America- Brazil, Argentina, Colombia, Rest of South America

☞ Middle East and Africa- Saudi Arabia, UAE, Oman, Bahrain, Qatar, Kuwait, Israel

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.